Girocitinib vs Soficitinib (ICP-332)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline

Girocitinib

Developed by Hangzhou Highlightll Pharmaceutical

small molecule
Partial signal

NCT05772520 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.

No aligned efficacy figure on record for this race.

Soficitinib (ICP-332)

Developed by Beijing InnoCare Pharma Tech Co.

Phase 2 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGirocitinibSoficitinib (ICP-332)
PASI 7535.5% vs 21.4%+14.1 vs placebowk 12 · n 31NCT05772520
5 other results
  • 44.8% vs 21.4% wk 12 · n 29 · Phase 2 · primary NCT05772520
  • 50% vs 21.4% wk 12 · n 8 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 61.1% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 8 · Phase 2 · primary NCT05772520
—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

Girocitinib
35.5% vs 21.4%+14.1 vs placebowk 12 · n 31NCT05772520
5 other results
  • 44.8% vs 21.4% wk 12 · n 29 · Phase 2 · primary NCT05772520
  • 50% vs 21.4% wk 12 · n 8 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 61.1% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 8 · Phase 2 · primary NCT05772520
Soficitinib (ICP-332)
—Not reported

PASI 90

Girocitinib
—Not reported
Soficitinib (ICP-332)
—Not reported

PASI 100

Girocitinib
—Not reported
Soficitinib (ICP-332)
—Not reported

sPGA 0/1

Girocitinib
—Not reported
Soficitinib (ICP-332)
—Not reported

DLQI, change

Girocitinib
—Not reported
Soficitinib (ICP-332)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Soficitinib (ICP-332): no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Girocitinib: 3 of 4 rows · Soficitinib (ICP-332): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGirocitinib
Dropout rate
22.6%Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
20.7%Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
0%Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
—Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
—Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
0%Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
0%Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
alanine aminotransferase increased 6.5% (placebo 7.1%)
headache 6.5% (placebo 0%)
leukopenia 6.5% (placebo 0%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
alanine aminotransferase increased 10.3% (placebo 7.1%)
aspartate aminotransferase increased 6.9% (placebo 0%)
neutropenia 6.9% (placebo 0%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
nasopharyngitis 12.5% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 7.1%)
alanine aminotransferase increased 0% (placebo 7.1%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Girocitinib

PASI 75 35.5% (n=31) vs 21.4% (n=14) placebo @ 12wk
responder rate · % of participants
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 11 Participants as posted
show 5 more results
44.8% (n=29) vs 21.4% (n=14) placebo @ 12wk*
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 13 Participants as posted
50% (n=8) vs 21.4% (n=14) placebo @ 12wk*
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 4 Participants as posted
50% (n=18) vs 25% (n=8) placebo @ 12wk*
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 9 Participants as posted
61.1% (n=18) vs 25% (n=8) placebo @ 12wk*
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 11 Participants as posted
50% (n=8) vs 25% (n=8) placebo @ 12wk*
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 · converted to % from 4 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Girocitinib's landscape · Soficitinib (ICP-332)'s landscape